This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999:14 Suppl 1:13-8.

The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease

M Vidailhet¹, A M Bonnet, R Marconi, F Durif, Y Agid

Affiliations

PMID: 10493399

Review

The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease

M Vidailhet et al. Mov Disord. 1999.

. 1999:14 Suppl 1:13-8.

Authors

M Vidailhet¹, A M Bonnet, R Marconi, F Durif, Y Agid

Affiliation

¹ Service de Neurologie, Hôpital Saint-Antoine, and U 289, Hôpital de la SalPêtrière, Paris, France.

PMID: 10493399

No abstract available

PubMed Disclaimer

Similar articles

Rating scales for dyskinesias in Parkinson's disease.
Goetz CG. Goetz CG. Mov Disord. 1999;14 Suppl 1:48-53. Mov Disord. 1999. PMID: 10493403 Review. No abstract available.
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Rascol O. Rascol O. Mov Disord. 1999;14 Suppl 1:19-32. Mov Disord. 1999. PMID: 10493400 Review. No abstract available.
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
Nutt J. Nutt J. Mov Disord. 1999;14 Suppl 1:74. Mov Disord. 1999. PMID: 10493408 No abstract available.
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F, Lilliu H, Le Pen C. Maurel F, et al. Rev Neurol (Paris). 2001 May;157(5):507-14. Rev Neurol (Paris). 2001. PMID: 11438770 French.
[Dyskinesia caused by L-DOPA].
Derkinderen P, Vidailhet M. Derkinderen P, et al. Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S92-101. Rev Neurol (Paris). 2002. PMID: 12690668 Review. French.

See all similar articles

Cited by

Non-human primate models of PD to test novel therapies.
Morissette M, Di Paolo T. Morissette M, et al. J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8. J Neural Transm (Vienna). 2018. PMID: 28391443 Review.
Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.
Barroso-Chinea P, Bezard E. Barroso-Chinea P, et al. Front Neuroanat. 2010 Sep 14;4:131. doi: 10.3389/fnana.2010.00131. eCollection 2010. Front Neuroanat. 2010. PMID: 20890450 Free PMC article.
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Heimer G, Bar-Gad I, Goldberg JA, Bergman H. Heimer G, et al. J Neurosci. 2002 Sep 15;22(18):7850-5. doi: 10.1523/JNEUROSCI.22-18-07850.2002. J Neurosci. 2002. PMID: 12223537 Free PMC article.
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
Dodel RC, Berger K, Oertel WH. Dodel RC, et al. Pharmacoeconomics. 2001;19(10):1013-38. doi: 10.2165/00019053-200119100-00004. Pharmacoeconomics. 2001. PMID: 11735671 Review.
Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism.
Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Heimer G, et al. J Neurosci. 2006 Aug 2;26(31):8101-14. doi: 10.1523/JNEUROSCI.5140-05.2006. J Neurosci. 2006. PMID: 16885224 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information